Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 10/2014

01-10-2014 | Gastrointestinal Cancers (BG Czito, Section Editor)

Colorectal Cancer with Potentially Resectable Hepatic Metastases: Optimizing Treatment

Authors: Mathias Worni, Kevin N. Shah, Bryan M. Clary

Published in: Current Oncology Reports | Issue 10/2014

Login to get access

Abstract

Colorectal cancer is a common malignancy and often presents with synchronous or metachronous distant spread. For patients with hepatic metastases, resection is the principal curative option. Liberalization of the indications for hepatic resection has introduced a number of challenges related to the size, distribution, and number of metastases as well as the condition of the future liver remnant. Advances in systemic therapy have solidified its role as both an important adjunct to surgery and also for many patients as a mechanism to facilitate resection. In patients whose disease is marginally resectable as a consequence of the distribution of hepatic lesions that precludes complete resection or out of concern for the future liver remnant, a number of strategies have been advocated, including prehepatectomy systemic therapy, staged surgical approaches, ablative technologies, and preoperative portal vein embolization. It is the purpose of this review to discuss ways in which to optimize the treatment of patients with potentially resectable disease, specifically those who are judged to have “borderline” resectable situations.
Literature
1.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64(1):9–29.PubMed
2.
Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12(7):825–39.PubMed
3.
Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol. 1996;12(4):219–52.PubMed
4.
Vauthey JN, Choti MA, Helton WS. AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases: rationale and overview of the conference. Ann Surg Oncol. 2006;13(10):1259–60.PubMed
5.
Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):91–103.PubMedCentral
6.•
Bonanni L, De'liguori Carino N, Deshpande R, et al. A comparison of diagnostic imaging modalities for colorectal liver metastases. Eur J Surg Oncol. 2014;40(5):545–50. This study highlights the importance of high-quality CT and MRI for assessment of metastatic tumor burden in the liver, while acknowledging the specific role of PET/CT and intraoperative ultrasonography.PubMed
7.
Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(16):1–243.
8.
Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–84.PubMed
9.
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
10.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.
11.
Ho WM, Ma B, Mok T, et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol. 2005;22(3):303–12.
12.
Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9.
13.
Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13(1):58–65.
14.
Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97(8):1035–9.
15.
Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil-leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemotherapy and Pharmacology. Jul 2008;62(2):195–201.
16.
Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5.
17.
Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.
18.
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47.
19.
Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663–71.
20.
Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with 803 FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) 804 as first-line treatment for metastatic colorectal cancer: a phase 2 805 trial. Lancet Oncol. 2010;11(9):845–52.
21.
Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.PubMed
22.
Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453–9.PubMedCentralPubMed
23.
Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706–13.PubMed
24.
Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.PubMed
25.
Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31(16):1931–8.PubMed
26.
Leone F, Artale S, Marino D, et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. MetaPan Study Cancer. 2013;119(19):3429–35.
27.••
Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5(4):221–34. This is a review of optimal systemic therapy for downsizing liver metastases to render disease resectable. First-line doublet chemotherapy regimens can achieve response rates of 50–60 %, with an increase to 70 % if triplet systemic therapy is used. Biologics can help to improve those rates.PubMedCentralPubMed
28.•
Bischof DA, Clary BM, Maithel SK, Pawlik TM. Surgical management of disappearing colorectal liver metastases. Br J Surg. 2013;100(11):1414–20. This is an overview article about the current treatment of patients with DLM during preoperative chemotherapy.PubMed
29.
Power DG, Kemeny NE. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol. 2011;79(3):251–64.PubMed
30.
Beppu T, Miyamoto Y, Sakamoto Y, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol. 2014;21(3 Suppl):405–13.
31.
Levi F, Karaboue A, Gorden L, et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2011;67(2):339–48.PubMed
32.
Bouchahda M, Adam R, Giacchetti S, et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 2009;115(21):4990–9.PubMed
33.
Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25(29):4593–602.PubMed
34.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.PubMedCentralPubMed
35.•
Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg. 2013;216(1):41–9. This study provides evidence that liver resection in patients with colorectal liver metastases can be performed safely even after preoperative chemotherapy.PubMed
36.
Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939–45.PubMed
37.
Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007;14(11):3188–94.PubMed
38.
Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010;116(6):1502–9.PubMed
39.
van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691–700.PubMed
40.
Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86(1):4–9.PubMed
41.
Peterhans M, Oliveira T, Banz V, Candinas D, Weber S. Computer-assisted liver surgery: clinical applications and technological trends. Crit Rev Biomed Eng. 2012;40(3):199–220.PubMed
42.
Satou S, Aoki T, Kaneko J, et al. Initial experience of intraoperative three-dimensional navigation for liver resection using real-time virtual sonography. Surgery. 2014;155(2):255–62.PubMed
43.
Arita J, Ono Y, Takahashi M, Inoue Y, Takahashi Y, Saiura A. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann Surg Oncol. 2014;21(3 Suppl):390–7.
44.
Reddy SK, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16(7):1809–19.PubMed
45.
Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252(5):774–87.PubMed
46.
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22. discussion 722-4.PubMedCentralPubMed
47.
de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248(4):626–37.PubMed
48.
Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.PubMed
49.••
Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149(5):713–24. This contains the newest guidelines by the International Study Group of Liver Surgery for defining PLF, which is mainly characterized by necessary clinical management.PubMed
50.
Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007;204(5):854–62. discussion 862-4.PubMed
51.
Rous P, Larimore LD. Relation of the portal blood to liver maintenance : a demonstration of liver atrophy conditional on compensation. J Exp Med. 1920;31(5):609–32.PubMedCentralPubMed
52.
Honjo I, Suzuki T, Ozawa K, Takasan H, Kitamura O. Ligation of a branch of the portal vein for carcinoma of the liver. Am J Surg. 1975;130(3):296–302.PubMed
53.
Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10(5):803–8.PubMed
54.
Vyas S, Markar S, Partelli S, et al. Portal vein embolization and ligation for extended hepatectomy. Indian J Surg Oncol. 2014;5(1):30–42.PubMed
55.
Vogl TJ, Balzer JO, Dette K, et al. Initially unresectable hilar cholangiocarcinoma: hepatic regeneration after transarterial embolization. Radiology. 1998;208(1):217–22.PubMed
56.
Denecke T, Seehofer D, Steffen IG, et al. Arterial versus portal venous embolization for induction of hepatic hypertrophy before extended right hemihepatectomy in hilar cholangiocarcinomas: a prospective randomized study. J Vasc Interv Radiol. 2011;22(9):1254–62.PubMed
57.•
Garlipp B, de Baere T, Damm R, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology. 2014;59(5):1864–73. This study provides evidence that PVE with the goal of contralateral liver hypertrophy and ipsilateral atrophy is superior to hepatic arterial embolization.PubMed
58.
Simoneau E, Aljiffry M, Salman A, et al. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford). 2012;14(7):461–8.
59.
Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology. 2001;34(2):267–72.PubMed
60.
Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg. 1999;86(6):784–8.PubMed
61.••
Fischer C, Melstrom LG, Arnaoutakis D, et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg. 2013;148(12):1103–8. This study highlights the benefit of interval chemotherapy between PVE and surgical resection. Patients in the chemotherapy group had lower tumor progression and longer 5-year survival compared with their counterparts.PubMed
62.
Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247(3):451–5.PubMed
63.
van Lienden KP, van den Esschert JW, de Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Interv Radiol. 2013;36(1):25–34.
64.
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15(10):2765–72.PubMed
65.
Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16(6):1553–9.PubMed
66.
Zalinski S, Bigourdan JM, Vauthey JN. Le bévacizumab a-t-il un effet protecteur sur l’hépatotoxicité induite par la chimiothérapie ? (Does bevacizumab have a protective effect on hepatotoxicity induced by chemotherapy?). J Chir (Paris). 2010;147 Suppl 1:S18–24.
67.
Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery. 2009;145(4):399–405.PubMed
68.
Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26(5):1176–81.PubMed
69.
Makuuchi M, Kosuge T, Takayama T, et al. Surgery for small liver cancers. Semin Surg Oncol. 1993;9(4):298–304.PubMed
70.
Shindoh J, Tzeng CWD, Vauthey JN. Portal vein embolization for hepatocellular carcinoma. Liver Cancer. 2012;1(3–4):159–67.PubMedCentralPubMed
71.
Cotroneo AR, Innocenti P, Marano G, Legnini M, Iezzi R. Pre-hepatectomy portal vein embolization: single center experience. Eur J Surg Oncol. 2009;35(1):71–8.PubMed
72.
Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237(2):208–17.PubMedCentralPubMed
73.
Madoff DC, Abdalla EK, Gupta S, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol. 2005;16(2 Pt 1):215–25.PubMed
74.
Kishi Y, Madoff DC, Abdalla EK, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery. 2008;144(5):744–51.PubMed
75.
Hwang S, Lee SG, Ko GY, et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy. Ann Surg. 2009;249(4):608–16.PubMed
76.
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405–14.PubMed
77.
Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232(5):665–72.PubMedCentralPubMed
78.•
Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg. 2013;216(2):201–9. This study compares the kinetic growth rate with the absolute radiographic volume change in patients after PVE. The kinetic growth rate performs better in predicting postoperative liver insufficiency.PubMedCentralPubMed
79.
Shindoh J, Tzeng CW, Aloia TA, et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg. 2013;100(13):1777–83.PubMed
80.•
Cardona K, Donataccio D, Peter Kingham T, et al. Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. Ann Surg Oncol. 2014;21(3):815–21. This study describes the feasibility of two-stage hepatic liver resection to clear the liver even of bilateral tumor burden.PubMed
81.
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in smallfor- size settings. Ann Surg, Mar 2012;255(3):405–414.
82.
Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford). 2013;15(7):483–91.
83.
Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29(8):1083–90.PubMedCentralPubMed
84.•
Nadalin S, Capobianco I, Li J, Girotti P, Konigsrainer I, Konigsrainer A. Indications and limits for associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Lessons learned from 15 cases at a single centre. Z Gastroenterol. 2014;52(1):35–42. This study describes the new technique of ALPPS.PubMed
85.
Shindoh J, Vauthey JN, Zimmitti G, et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg. 2013;217(1):126–33. discussion 133-4.PubMed
86.•
Saied A, Katz SC, Espat NJ. Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases. Hepatobiliary Surg Nutr. 2013;2(2):97–107. This study describes the different modalities available for regional hepatic therapies.PubMedCentralPubMed
87.
Reissfelder C, Rahbari NN, Bejarano LU, et al. Comparison of various surgical approaches for extensive bilateral colorectal liver metastases. Langenbecks Arch Surg. 2014;399(4):481–91.PubMed
88.
Stoltz A, Gagniere J, Dupre A, Rivoire M. Radiofrequency ablation for colorectal liver metastases. J Visc Surg. 2014;151 Suppl 1:S33–44.PubMed
89.
Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol. 2005;90(1):36–42.PubMed
90.
Chua TC, Liauw W, Chu F, Morris DL. Summary outcomes of two-stage resection for advanced colorectal liver metastases. J Surg Oncol. 2013;107(2):211–6.PubMed
91.
Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology. 2004;51(60):1788–91.PubMed
92.
93.
Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003;90(10):1240–3.PubMed
94.
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25. discussion 825-7.PubMedCentralPubMed
95.
Otto G, Duber C, Hoppe-Lotichius M, Konig J, Heise M, Pitton MB. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg. 2010;251(5):796–803.PubMed
96.
Aliyev S, Agcaoglu O, Aksoy E, et al. Efficacy of laparoscopic radiofrequency ablation for the treatment of patients with small solitary colorectal liver metastasis. Surgery. 2013;154(3):556–62.PubMed
97.
Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36.PubMed
98.
Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141(5):460–6. discussion 466-7.PubMed
99.
Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;(6):CD006317.
100.••
Karanicolas PJ, Metrakos P, Chan K, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2014;21(1):e129–36. This contains an expert consensus statement summarizing the current evidence for hepatic arterial infusion chemotherapy.PubMedCentralPubMed
101.
Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–26.PubMed
102.
Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23(22):4881–7.PubMed
103.
Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71.PubMedCentralPubMed
104.
Goere D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91.PubMed
105.
Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000;7(7):490–5.PubMed
106.
Pulitano C, Arru M, Catena M, et al. Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol. 2008;15(6):1661–9.PubMed
107.
Hagness M, Foss A, Egge TS, Dueland S. Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2014;21(4):1323–9.PubMedCentralPubMed
108.•
Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257(5):800–6. This study describes liver transplantation in patients with unresectable colorectal liver metastases. Outcomes are compared with those of patients undergoing palliative chemotherapy only, providing evidence that overall survival can be significantly prolonged. They achieve an overall survival comparable to that of patients undergoing liver resection for resectable colorectal liver metastases.PubMed
109.
Foss A, Adam R, Dueland S. Liver transplantation for colorectal liver metastases: revisiting the concept. Transpl Int. 2010;23(7):679–85.PubMed
110.
111.
Worni M, Mantyh CR, Akushevich I, Pietrobon R, Clary BM. Is there a role for simultaneous hepatic and colorectal resections? A contemporary view from NSQIP. J Gastrointest Surg. 2012;16(11):2074–85.PubMed
112.
Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14(12):3481–91.PubMed
113.
Yoshioka R, Hasegawa K, Mise Y, et al. Evaluation of the safety and efficacy of simultaneous resection of primary colorectal cancer and synchronous colorectal liver metastases. Surgery. 2014;155(3):478–85.PubMed
114.
de Rosa A, Gomez D, Hossaini S, et al. Stage IV colorectal cancer: outcomes following the liver-first approach. J Surg Oncol. 2013;108(7):444–9.PubMed
115.
Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210(6):934–41.PubMed
116.
Mentha G, Roth AD, Terraz S, et al. ‘Liver first’ approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg. 2008;25(6):430–5.PubMed
117.
de Jong MC, van Dam RM, Maas M, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford). 2011;13(10):745–52.
Metadata
Title
Colorectal Cancer with Potentially Resectable Hepatic Metastases: Optimizing Treatment
Authors
Mathias Worni
Kevin N. Shah
Bryan M. Clary
Publication date
01-10-2014
Publisher
Springer US
Published in
Current Oncology Reports / Issue 10/2014
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0407-z
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits